Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Tickers JSPR
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Tickers JSPR
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Tickers JSPR
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Tickers JSPR
Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
From Jasper Therapeutics, Inc.
Via Business Wire
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members
From Jasper Therapeutics, Inc.
Via Business Wire
Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes
From Jasper Therapeutics, Inc.
Via Business Wire
Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant
From Jasper Therapeutics, Inc.
Via Business Wire
Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting
From Jasper Therapeutics, Inc.
Via Business Wire
Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease
From Jasper Therapeutics, Inc.
Via Business Wire
Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
From Jasper Therapeutics, Inc.
Via Business Wire
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation
From Jasper Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.